25 results about "Dihydrotestosterone" patented technology

Disclosed are pharmaceutical and cosmetic compositions that include 5 Alpha Dihydrotestosterone (or alternatively, 5α-DHT, 5 Alpha-DHT, 5 Alpha DHT, 5a-DHT, DHT), and associated methods of use and treatment that can be used alone or in combination with other treatments to provide, improve, or promote general well-being and health, including mental health, in a subject. In particular the compositions, methods, and uses can provide, promote, support, and / or improve outcomes associated with gender reassignment, gender transitioning, and / or gender-affirming therapy in a subject who may be in need thereof.

Provided is the composition capable of effectively exerting an effect on a change in a hormone balance. A composition for inhibiting the decrease in endogenous testosterone and / or dihydrotestosterone, the composition comprising Cordyceps militaris derived from Samia cynthia ricini and / or its extract is prepared.

The invention provides a traditional Chinese medicine composition for preventing hair loss and promoting hair growth and application thereof, and relates to the technical field of hair loss prevention and promoting hair growth, the traditional Chinese medicine composition is composed of Chinese doughnut, cockscomb, albizia flower, Chinese honey locust, schizonepeta, lithospermum, polygonum multiflorum, prepared rehmannia root, notopterygium root, radix angelicae pubescentis, ruddle and periostracum cicada; in-vitro experiments show that the traditional Chinese medicine composition can promote proliferation of human dermal papilla cells HDPC, relieve the damage degree of HDPC and induce cycle transformation of hair follicles, so that the effect of promoting hair growth is achieved; animal experiments show that the traditional Chinese medicine composition can significantly increase the number of hair follicles and the thickness of skin and dermis fat of mice, reduce the levels of mouse serum IL-2, TNF-alpha and TGF-beta1 and reduce the levels of testosterone, dihydrotestosterone and estradiol in mouse skin tissue, so that hair follicle fibrosis is inhibited, the growth period of hair follicles is accelerated, the growth period is prolonged, the hair loss phenomenon is improved, and the hair loss rate is increased. The hair growth is promoted.

The present disclosure describes a method for preventing or treating an abnormal mammary gland cytopathy characterized by cell proliferation in a subject. The method comprises administering to the subject an effective amount of an androgen agent in combination with an effective amount of an aromatase inhibitor, increasing the concentration of the androgen agent in serum to a level to increase the intramammary concentration of androgen in the mammary gland resulting from the action of 5 alpha-reductase on the androgen agent, the increased intramammary concentration of the androgen induces inhibition of c-Myc and / or mTOR expression or activity in the mammary gland associated with a lower intramammary concentration of the androgen. The increase in the serum concentration of the androgen agent and the increase in the intramammary concentration of the androgen are maintained for a predetermined period of time without substantially increasing the concentration of the androgen in the serum of the subject. Furthermore, the use of the aforementioned androgen and aromatase inhibitors for reducing the risk of breast cancer progression to hormone-resistant breast cancer, reducing the risk of HER2-positive breast cancer becoming insensitive to targeted HER-2 anti-cancer drug therapy, and for inducing inhibition of c-Myc and / or mTOR expression and / or activity is also described. In embodiments, the androgen agent may be testosterone and androgen 5 [alpha]-dihydrotestosterone (DHT).

The present invention relates to a composition for preventing, ameliorating or treating benign prostatic hyperplasia, containing a Hovenia dulcis extract as an active ingredient. Specifically, the Hovenia dulcis extract of the present invention was confirmed to inhibit the proliferation of hyperproliferative prostatic cells induced by dihydrotestosterone (DHT), which is a male hormone, and reduce prostate weight in an animal model with induced benign prostatic hyperplasia, and thus can be effectively used as a composition for preventing, ameliorating or treating benign prostatic hyperplasia.

Novel chemical agents are described herein. More specifically, a novel inhibitor of 17β-HSD7 for decreasing estradiol concentrations while restoring dihydrotestosterone (DHT) concentrations in breast cancer cells is disclosed herein. In a particular embodiment, the inhibitor of 17β-HSD7 has the following structure: (Formula I) A process for producing the novel inhibitors of 17β-HSD7 and their use in the manufacture of pharmaceutical formulations and / or combinations is also disclosed.

The application relates to the technical field of biology, and discloses a method for inducing a cell line of immortalized musk deer scent glands to synthesize dihydrotestosterone, wherein the cell line is obtained by transfecting a primary musk deer scent gland epithelial cell with a lentivirus carrying an SV40 Large T antigen and performing resistance screening; the cell line is in an epithelial cell form and stably expresses keratin 18, cholesterol side chain cleavage enzyme, 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase. Through lentivirus-mediated SV40 Large T antigen transfection, the primary musk deer scent gland epithelial cell breaks through the limit of replicative senescence and obtains unlimited proliferation capacity, effectively overcomes the defects that the primary cell is prone to fibrosis and rapidly loses metabolic function during in-vitro culture, provides a standardized cell model with a clear genetic background and persistent metabolic activity for biological manufacturing of dihydrotestosterone, and relieves the dependence on endangered animal live resources.

The present invention relates to a composition for preventing or treating male pattern hair loss by adsorption and / or removal of dihydrotestosterone (DHT), and uses thereof, wherein the composition comprises a metal-organic framework, which penetrates hair follicles and, by adsorbing and / or removing DHT, can exhibit preventive or therapeutic effects against the progression of hair loss. In addition, when the composition is applied to the scalp as a hair serum or a hair cream comprising the metal-organic framework, the metal-organic framework penetrates hair follicles and can continuously adsorb / remove DHT that is continuously released in the body, and the metal-organic framework that has adsorbed and / or removed DHT can be discharged to the outside as the hair grows.

The application provides application of echinocystic acid in preparation of a 5alpha-reductase type II inhibitor product. In-vitro tests prove that the echinocystic acid has obvious inhibitory effect on 5alpha-reductase type II activity; experimental testosterone-induced androgenic alopecia mouse models prove that the echinocystic acid can promote hair growth of the mice and reduce dihydrotestosterone content in the skin of the mice, and can be used for preparing a product for inhibiting 5alpha-reductase type II activity and treating androgenic alopecia.

The invention discloses application of a semen nigellae extract in preparation of a product for preventing and / or treating androgenetic alopecia. The total content of nigella alkaloid and nigella alkaloid 4-O-sulfite in the nigella seed extract is not less than 2%. The preparation process comprises the following steps: degreasing nigellum nigrum medicinal material powder with petroleum ether, extracting with an acidic aqueous solution, and enriching with macroporous adsorption resin and specifically purifying with anion exchange resin in sequence. Experiments show that the extract can most significantly reduce the levels of testosterone (T), dihydrotestosterone (DHT) and creatinine (Cr) in an androgenetic alopecia model mouse body, increase the level of estradiol (E2) and effectively promote back hair regeneration, and the effect of the extract is significantly superior to that of a water extract, an alcohol extract and a positive control drug. The extract is clear in component and controllable in quality, can be used for preparing medicines or wash supplies with multi-target anti-hair loss and hair growth functions, and provides a novel efficient natural raw material for treating androgenetic alopecia.

Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cells and / or hyperplastic cells and / or treating individuals having diseases associated with malignant cell growth (e.g., cancer, such as, for example, prostate cancer) and / or hyperplastic cell growth and / or molecular imaging of malignant cells and / or hyperplastic cells and / or inducing degradation of a target protein. Also provided are compositions.

The invention belongs to the technical field of biomedical cosmetics, and discloses a double-target 5alpha-reductase and adiponectin receptor cyclic peptide as well as application and a preparation method thereof. The cyclic peptide is formed by cyclizing three amino acid units, namely arginine, phenylalanine and tyrosine through peptide bonds, and comprises pharmaceutically acceptable salts, solvates, stereoisomers or isotope labels of the cyclic peptide. The compound reduces generation of dihydrotestosterone by inhibiting 5alpha-reductase, activates an adiponectin receptor AdipoR pathway to promote energy metabolism and proliferation of hair papilla cells, and realizes double-target synergistic anti-alopecia. The invention also discloses application of the cyclopeptide in preparation of medicines or cosmetics for preventing or treating alopecia and a solid-phase synthesis preparation method. Through double-target synergistic interaction, the hair follicle cell proliferation rate can be remarkably increased at extremely low concentration, and the dosage is reduced compared with that of a traditional medicine; the composition is constructed by adopting physiological amino acid, has no systemic sex hormone side effect during local external use, and is high in safety.

This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), lerociclib, abemaciclib (Vorzenio), trilaciclib, lerociclib), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and / or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound and a cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor.

The present invention relates to a composition for preventing, ameliorating or treating benign prostatic hyperplasia, containing Hovenia dulcis honey as an active ingredient. Specifically, the Hovenia dulcis honey of the present invention suppresses the proliferation of prostate cells that are hyperproliferated by dihydrotestosterone (DHT), which is a male hormone, and has the effect of reducing prostate weight in an animal model with induced benign prostatic hyperplasia, and thus can be effectively used as a composition for preventing, ameliorating or treating benign prostatic hyperplasia.

This invention relates to the field of pharmaceutical technology and discloses the application of mitochondrial quinone in the intervention and treatment of androgenetic alopecia. This invention explores the application and related molecular mechanisms of mitochondrial quinone in alleviating hair loss in mice stimulated by DHT, clarifying the effectiveness of mitochondrial quinone in inhibiting abnormal hair follicle growth and promoting hair regeneration in mice induced by dihydrotestosterone. This provides experimental evidence for the clinical application of mitochondrial quinone in the intervention and treatment of hair loss diseases, especially androgenetic alopecia, and offers another safe and effective substance for the effective prevention and treatment of androgenetic alopecia.

This invention relates to the field of biomedicine, specifically disclosing an antibody for treating benign prostatic hyperplasia (BPH) and its applications. The antibody is a nanobody containing a complementary determinant region (CDR) sequence as shown in SEQ ID NO:5. This invention provides a method for preparing the antibody and demonstrates that it effectively antagonizes the binding of GnRH to GnRHR, thereby inhibiting cAMP production mediated by the GnRH signaling pathway and reducing the levels of testosterone, dihydrotestosterone, and luteinizing hormone. In vivo pharmacodynamic experiments show that the antibody provided by this invention can significantly improve the prostate weight / body weight ratio in a rat model of benign prostatic hyperplasia, exhibiting a good therapeutic effect on BPH and providing a new candidate drug for the clinical treatment of BPH.

This invention provides a composition containing lactic acid bacteria and its use in lowering dihydrotestosterone and improving hyperandrogenemia. The composition can lower dihydrotestosterone and improve androgenemia. The lactic acid bacteria comprise *Lactobacillus helveticus* GKS3, *Lactobacillus brevis* GKL9, *Lactobacillus johnsonii* GKJ2, *Pediococcus acidilactici* GKA4, or a combination thereof.

The invention discloses a ribonucleic acid and natural product combined anti-hair loss composition and application thereof. The invention relates to a composition for treating androgenetic alopecia, which comprises a cupressus sempervirens cones extract (CSE), 5, 7-dihydroxyflavone (DHF) and a small interfering RNA (siRNA) which is specifically chemically modified and is targeted to an androgenetic alopecia key gene SRD5A2 and / or AR. Cell and animal models verify that the composition with the optimal proportion of the components has the effects of promoting hair growth, increasing the number of hair follicles, reducing the levels of local dihydrotestosterone (DHT) and inflammatory factors and the like, and the effects of the composition are remarkably superior to those of a traditional compound and a positive control. Based on this, the invention provides a new scheme for preventing and / or treating androgenetic alopecia.

The application discloses a 21-hydroxylase deficiency screening kit and application thereof, relates to the blood analysis technical field, and a steroid hormone marker composition of 21-hydroxylase deficiency, wherein the nine markers comprise 17alpha-hydroxyprogesterone, androstenedione, 11-deoxycortisol, 21-deoxycortisol, cortisol, corticosterone, progesterone, dihydrotestosterone and 11-deoxycorticosterone; the kit can be used for screening 21-hydroxylase deficiency, 11beta-hydroxylase deficiency, 17alpha-hydroxylase deficiency and other types of diseases; the kit comprises detection components for detecting the hormones; compared with a traditional time-resolved fluorescence immunoassay method, the LC-MS / MS multi-index combined detection scheme adopted in the application can significantly reduce false positive results; and invalid recall, unnecessary family anxiety and medical burden caused by false positive results are greatly reduced.

The present application relates to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition and preparation and application thereof. The composition provided by the present application comprises Ramulus cinnamomi, Poria cocos, Cortex moutan, Semen persicae, Radix paeoniae alba, Radix rubiae, Cornus officinalis, and Rhizoma sparganii. The composition can obviously reduce the prostate index and prostate epithelial thickness of a benign prostatic hyperplasia model rat, and relieve interstitial edema. The experimental results show that the composition can obviously reduce the content of dihydrotestosterone, estradiol, testosterone, gonadotropin-releasing hormone, and rat luteinizing hormone in the prostate serum of a model mouse, and increase the content of follicle-stimulating hormone. The above results show that the traditional Chinese medicine composition can inhibit sex hormone disorder, and has the effect of treating prostatic hyperplasia.

The invention discloses an exosome for treating androgenetic alopecia and application thereof, and belongs to the technical field of biomedicine. The exosome is derived from a human hair papilla cell of overexpression LINC01609. The research result shows that the LINC01609 is obviously reduced in the hair papilla cells of the AGA patient; the engineered exosome obtained by transfecting the overexpression vector can significantly enhance the proliferative activity of hair follicle stem cells (HFSCs). Animal experiments show that the exosome provided by the invention can effectively reverse hair follicle microminiaturization induced by dihydrotestosterone (DHT), so that the hair coverage rate is increased to 92.5% or above, and the diameter of the hair follicle is increased by about 47.6%. Therefore, the invention provides a safe and efficient novel biological means for precise treatment of AGA, and has wide clinical application prospects.

Provided herein are antigen binding protein-drug conjugates and compositions thereof that are useful, for example, for target-specific delivery of therapeutic moieties, such as testosterone analogs and / or derivatives. Dihydrotestosterone analogs, antibody-drug conjugates, and compositions comprising glutaminyl modified antibodies and dihydrotestosterone analogs are provided.

The invention discloses a traditional Chinese medicine composition for treating androgenetic alopecia and a preparation method thereof. The traditional Chinese medicine composition is prepared from 12-36 parts of wine-processed glossy privet fruit, 10-30 parts of prepared polygonum multiflorum, 15-45 parts of mulberry, 12-36 parts of eclipta, 10-30 parts of radix paeoniae alba, 20-60 parts of astragalus membranaceus, 12-36 parts of bighead atractylodes rhizome, 12-36 parts of poria cocos and 6-18 parts of honey-fried licorice root. The medicine composition and the specific dosage are obtained through a large number of experimental screening and clinical medication experience screening. The traditional Chinese medicine composition is prepared from nine traditional Chinese medicines, and has a remarkable treatment effect on spleen-kidney deficiency and liver depression type AGA on the basis of the traditional Chinese medicine theory of'simultaneous regulation of liver, spleen and kidney and co-treatment of essence, qi and blood '. The content of testosterone, estradiol and dihydrotestosterone in mouse serum is detected through ELISA (enzyme-linked immuno sorbent assay). Results show that the new hair area and the hair length of the mouse back unhairing area can be increased to different degrees, the hair blackening time can be shortened, and scanning electron microscope results show that the traditional Chinese medicine composition can improve the hair form and promote the hair to become thick and smooth, and hair cuticles are densely arranged.

The invention discloses an application of homogra albizzia triterpenic acid in preparation of a product for preventing and / or treating alopecia. The alopecia is preferably androgenetic alopecia. It is found for the first time that on one hand, the natural triterpenic acid can effectively inhibit the activity of 5 alpha-reductase, and generation of a pathogenic factor dihydrotestosterone is reduced from the source; on the other hand, human hair follicle dermal papilla cell apoptosis caused by dihydrotestosterone can be directly inhibited, and cell proliferation is promoted. The albizzia chinensis triterpenic acid can be applied to preparation of products for preventing and / or treating alopecia, new application of the albizzia chinensis triterpenic acid is provided, and a new choice is provided for preventing and treating alopecia.

The present invention relates to a composition for preventing, alleviating or treating prostatic hyperplasia, containing a hemp extract as an active component. Specifically, in the present invention, it has been confirmed that the hemp extract inhibits the proliferation of prostate cells hyperproliferated by dihydrotestosterone (DHT), which is a male hormone, and reduces weight of the prostate in an animal model in which prostatic hyperplasia is induced, and thus can be effectively used as a composition for preventing, alleviating or treating prostatic hyperplasia.